Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3999099 | 0.93 | CNR2 (0.69) | CNR2 | |
| SCHEMBL2205211 | 0.89 | CNR2 (0.74) | CNR2CNR1 | |
| SCHEMBL3998418 | 0.88 | CNR2 (1.00) | CNR2CNR1 | |
| Hydrochloric Acid SCHEMBL3999411 | 0.87 | CNR2 (0.98) | CNR2CNR1 | |
| SCHEMBL3368007 | 0.87 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL2205100 | 0.86 | CNR2 (0.83) | CNR2CNR1 | |
| SCHEMBL1335880 | 0.85 | CNR2 (0.86) | CNR2CNR1 | |
| SCHEMBL3998186 | 0.85 | CNR2 (0.78) | CNR2CNR1 | |
| SCHEMBL3367232 | 0.85 | CNR2 (0.81) | CNR2CNR1 | |
| SCHEMBL3368400 | 0.84 | CNR2 (0.81) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342199-B1 | Sulfonyl compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INT (DE) | 2014-02-26 | — | — | EP | disclosed |
| US-8372874-B2 | Compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-12 | — | — | US | disclosed |
| EP-1994011-B1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | RAQUALIA PHARMA INC (JP) | 2010-10-13 | — | — | EP | disclosed |
| US-7700618-B2 | Sulfonyl benzimidazole derivatives | PFIZER INC (US) | 2010-04-20 | — | — | US | disclosed |
| WO-2010036631-A2 | COMPOUNDS WHICH SELECTIVELY MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| US-20100076029-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-25 | — | — | US | disclosed |
| US-7598393-B2 | Sulfonyl benzimidazole derivatives | PFIZER INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090137584-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | RAQUALIA PHARMA INC. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1809607-B1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1994011-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | Pfizer, Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007102059-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | PFIZER JAPAN INC. (JP) | 2007-09-13 | — | — | WO | disclosed |
| EP-1809607-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | Pfizer, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006048754-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | PFIZER JAPAN INC. (JP) | 2006-05-11 | — | — | WO | disclosed |
| US-20060094750-A1 | Sulfonyl benzimidazole derivatives | KON-I KANA | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137584-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | TRPV1, CNR2, CNR1 | CNR2 2/4885CNR1 3/4885 |
| US-20100076029-A1 | Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885 |
| US-20060094750-A1 | Sulfonyl benzimidazole derivatives | TRPV1, CNR2, CNR1 | CNR2 2/4885CNR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.